肝癌经肝动脉化疗栓塞治疗综述
|
摘要
原发性肝癌(下文简称为肝癌)为临床上常见恶性肿瘤之一,其中超过百分之九十为肝细胞肝癌(HCC)。肝癌每年全球以超过62.5万的发病率发展,每一年超过一半的患者发生在我国,肝癌在全世界癌症发病率的第三位。肝癌的诊治水平可延长其生命,因此诊治水平变得尤为重要。近些年来,手术切除治疗、介入治疗、化疗栓塞以及各种消融治疗的不断的完善和发展,特别是介入治疗,已经成为超过一半的肝癌患者的首选治疗,已有效取代传统手术治疗。介入治疗有效的提升了患者的生存期,有效的改善了患者的生活质量,取得了显著的治疗效果。本文主要对介入治疗具有的价值展开论述,希望能够为原发性肝癌患者的治疗提供科学建议。
Primary liver cancer(hereinafter referred to as liver cancer) is one of the most common malignant tumors in the clinic, and more than 90% of them are hepatocellular carcinoma(HCC). Liver cancer develops globally with an annual incidence of more than 625,000. More than half of the patients in each year occur in China, and liver cancer ranks third in the world in cancer incidence. The diagnosis and treatment of liver cancer can prolong its life, so the level of diagnosis and treatment becomes more important. In recent years, the continuous improves the patient's quality of life, and achieves significant therapeutic effects. This article mainly discusses the value of interventional therapy, and hopes to provide scientific advice for the treatment of patients with primary liver cancer.
Primary liver cancer(hereinafter referred to as liver cancer) is one of the most common malignant tumors in the clinic, and more than 90% of them are hepatocellular carcinoma(HCC). Liver cancer develops globally with an annual incidence of more than 625,000. More than half of the patients in each year occur in China, and liver cancer ranks third in the world in cancer incidence. The diagnosis and treatment of liver cancer can prolong its life, so the level of diagnosis and treatment becomes more important. In recent years, the continuous improves the patient's quality of life, and achieves significant therapeutic effects. This article mainly discusses the value of interventional therapy, and hopes to provide scientific advice for the treatment of patients with primary liver cancer.
引文
[1]游国超,高毅,张强.复方苦参注射液联合介入疗法治疗原发性肝癌疗效及对患者肝功能影响[J].陕西中医, 2018, 39(12):1722-1724.
[2]李浩.肝动脉化疗栓塞术配合PEI介入治疗原发性肝癌的临床效果分析[J].中外医疗, 2018, 37(32):71-73.
[3]喻小静,蔡惠,李强,等.升荣口服液联合肝动脉介入化疗栓塞治疗原发性肝癌疗效及机制研究[J].中西医结合肝病杂志, 2018,28(5):275-277.
[4]孙德勇,黄景民.肝动脉介入化疗栓塞术与还原型谷胱甘肽治疗对晚期肝癌患者肝功能恢复的影响[J].中国老年保健医学, 2018,16(5):114-117.
[5]郑操,张荣胜,潘勇,等.金龙胶囊与介入治疗原发性肝癌的疗效及对T淋巴细胞亚群、肿瘤免疫因子的影响[J].现代消化及介入诊疗, 2018, 23(4):506-509.
[6]魏秋良,蔡珊珊.中晚期原发性肝癌TACE介入微创治疗疗效和对肝功能影响观察[J].中华肿瘤防治杂志, 2018, 25(18):1314-1317.
[7]黄秋峰,李忱瑞,许飞,等.明胶海绵颗粒与海藻酸钠微球经动脉化疗栓塞治疗原发性肝癌对比研究[J].中国介入影像与治疗学,2016, 13(4):195-199.
[8]刘嘉龙,黄登,曹利,等.腹腔镜肝切除术和射频消融术治疗复发性肝癌的前瞻性随机对照研究(中期随访分析)[J].第三军医大学学报:2018, 11(5):1-7.
[9]李少明,汤万荣,李薇,等.经肝动脉化疗栓塞联合射频消融术对术中晚期原发性肝癌的近期疗效分析[J].中国医药科学, 2018,8(22):223-225.
[10]王晓辉,王立博,尹向岩.丝裂霉素联合碘油经肝动脉介入栓塞治疗中晚期肝癌的有效性与经济学评价[J].中西医结合肝病杂志, 2016, 26(6):346-348.
[2]李浩.肝动脉化疗栓塞术配合PEI介入治疗原发性肝癌的临床效果分析[J].中外医疗, 2018, 37(32):71-73.
[3]喻小静,蔡惠,李强,等.升荣口服液联合肝动脉介入化疗栓塞治疗原发性肝癌疗效及机制研究[J].中西医结合肝病杂志, 2018,28(5):275-277.
[4]孙德勇,黄景民.肝动脉介入化疗栓塞术与还原型谷胱甘肽治疗对晚期肝癌患者肝功能恢复的影响[J].中国老年保健医学, 2018,16(5):114-117.
[5]郑操,张荣胜,潘勇,等.金龙胶囊与介入治疗原发性肝癌的疗效及对T淋巴细胞亚群、肿瘤免疫因子的影响[J].现代消化及介入诊疗, 2018, 23(4):506-509.
[6]魏秋良,蔡珊珊.中晚期原发性肝癌TACE介入微创治疗疗效和对肝功能影响观察[J].中华肿瘤防治杂志, 2018, 25(18):1314-1317.
[7]黄秋峰,李忱瑞,许飞,等.明胶海绵颗粒与海藻酸钠微球经动脉化疗栓塞治疗原发性肝癌对比研究[J].中国介入影像与治疗学,2016, 13(4):195-199.
[8]刘嘉龙,黄登,曹利,等.腹腔镜肝切除术和射频消融术治疗复发性肝癌的前瞻性随机对照研究(中期随访分析)[J].第三军医大学学报:2018, 11(5):1-7.
[9]李少明,汤万荣,李薇,等.经肝动脉化疗栓塞联合射频消融术对术中晚期原发性肝癌的近期疗效分析[J].中国医药科学, 2018,8(22):223-225.
[10]王晓辉,王立博,尹向岩.丝裂霉素联合碘油经肝动脉介入栓塞治疗中晚期肝癌的有效性与经济学评价[J].中西医结合肝病杂志, 2016, 26(6):346-348.